Evidence map›Paper›PMID 38510652›Full record

ArticleFrontiers in pharmacology2024

Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes.

Ninoschka C D'Souza, Julian A Aiken, Emily G Hoffman, Sara C Atherley, Sabrina Champsi, Nadia Aleali, Dorsa Shakeri, Maya El-Zahed, Nicky Akbarian, Mehran Nejad-Mansouri and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Ninoschka C D'SouzaSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Julian A AikenSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Emily G HoffmanSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Sara C AtherleySchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Sabrina ChampsiSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Nadia AlealiSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Dorsa ShakeriSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Maya El-ZahedSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Nicky AkbarianSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Mehran Nejad-MansouriSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Parinaz Z BavaniSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
Richard L LigginsZucara Therapeutics, Vancouver, BC, Canada.
Owen ChanDepartment of Internal Medicine, Division of Endocrinology, University of Utah, Salt LakeCity, UT, United States.
Michael C RiddellSchool of Kinesiology and Health Science, York University, Toronto, ON, Canada.
York University · CAUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

counterregulationglucagonhypoglycemiasomatostatin receptor antagonisttype 2 diabetes

Identifiers

PMID38510652
PMCPMC10951717
OpenAlexW4392235779

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.